What Is BPC-157?

BPC-157 is a short synthetic peptide that turns up widely in preclinical research. Unlike the large incretin agonists profiled elsewhere here, it is a compact chain of fifteen amino acids, a pentadecapeptide. This profile explains what the molecule is, where its sequence is described as originating, and the research contexts in which it has been examined. It is background for handling the material in a laboratory and does not describe or imply any use.

The literature describes BPC-157 as a peptide corresponding to a partial sequence found within a protein in gastric juice; the abbreviation reflects the “body protection compound” terminology used in that early work. The research material is not extracted but made synthetically, which is what allows a defined, repeatable sequence to be produced and characterised batch after batch. The solid-phase approach typically used for peptides of this length is outlined in how peptides are manufactured.

As a pentadecapeptide, BPC-157 is fifteen residues in a defined order. Its small size sets it apart from protein fragments and large engineered peptides, and is one reason it is often noted in the literature for stability as a synthetic sequence. The material is handled as a lyophilised powder, as listed on the BPC-157 product page; for the residue notation in a specification, see peptide sequence notation.

BPC-157 is described as a partial sequence rather than a complete protein found intact in nature, which is one reason it is prepared synthetically for study. Its compact size is also the practical reason its identity and purity can be confirmed with a fairly standard analytical toolkit, making it convenient to characterise to a specification.

Two things draw research attention: the sequence’s described origin in a gastric protein, and its convenience as a small, synthetically accessible peptide. Short peptides are comparatively easy to synthesise, purify and characterise, and their size makes the link between sequence and behaviour easier to reason about than for large proteins. Those practical qualities help explain why BPC-157 recurs across preclinical studies, quite apart from any single research question.

In the literature, BPC-157 has been examined chiefly in preclinical models, with reported work across tissue and gastrointestinal research contexts. These studies describe how the peptide behaves in particular experimental systems and read properly as observations within those systems. A related research peptide is introduced in what is TB-500?, and both, with their combination, appear in the research catalogue.

Most published work on BPC-157 is preclinical, so its findings sit best as exploratory leads. The literature is uneven in scope, which puts a premium on tracing claims back to their original studies. The BPC-157 research overview looks at the investigated mechanisms and the limits of that evidence in more detail.

All products are supplied strictly for laboratory research use only. Not for human or animal consumption. Not a drug, supplement, or food. Not for diagnostic or therapeutic use. The material on this page is educational and factual: it summarises areas of published scientific investigation and general laboratory practice. It is not guidance for the use of any material in humans or animals, and nothing here should be read as a claim about safety, performance, or outcomes. Where a specific product specification or safety data sheet is provided with a material, that document is the definitive reference and takes precedence over any general information given here.